Featured News

The Celiac Disease Foundation, is proud to announce a recent grant of $200,000 from the Foster Family Foundation, which CDF will use to further its mission.

The Celiac Disease Foundation today announces the departure of Chief Development Officer Deborah Ceizler, who has served in key roles for more than 18 years.

Research is pivotal to the mission of the Celiac Disease Foundation, and so I’m excited to provide you with an update on the groundbreaking findings of a recent study conducted for the European Union’s Joint Research Centre (JRC).

Want to get involved in celiac disease research? It’s time to take action. The TEV-CeD Study is a phase 1b clinical trial testing the investigational medication TEV-53408 for the treatment of celiac disease.  

New research indicates that a specific set of natural memory T cells, when triggered by gluten, rapidly become destructive and cause intestinal damage in celiac disease patients.

Congratulations to Celiac Disease Foundation research partner Takeda Pharmaceuticals and its Medical Director Dan Leffler on recent media attention for three potential celiac disease therapies.

During the month of May, the Celiac Disease Foundation is taking the opportunity to honor the advocacy efforts of our dedicated, inspiring celiac disease patient community.

During May, Celiac Disease Awareness Month, the Celiac Disease Foundation wants to take this opportunity to honor the advocacy efforts of our dedicated, inspiring celiac disease patient community.

DDW 2023 showcased some of the latest research and innovations in celiac disease. These included promising early results from four investigational medications currently being tested for the treatment of celiac disease, as well as CDF research conducted in partnership with Takeda and Adelphi Real World.

The ILLUMINATE Studies are phase 2 clinical research studies evaluating an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.